Joshua Rabinowitz, M.D., Ph.D.

Dr. Joshua Rabinowitz is a professor of chemistry & integrative genomics at Princeton University, and director of the Ludwig Princeton Branch. He brings a quantitative, chemical perspective to the study of diet and metabolism. His research focuses on two broad questions: What is the quantitative flow (flux) through different metabolic pathways? How is this flux controlled? To address these questions, his lab develops innovative technologies that blend mass spectrometry, isotope tracers, and computational data integration. These technologies have been broadly applied to address major biomedical problems, including diabetes and cancer. Dr. Rabinowitz contributed to the discovery of the cancer-causing metabolite, 2-hydroxyglutarate, and to lactate’s role as a major circulating fuel.

After obtaining his M.D. and a Ph.D. in biophysics from Stanford University, Dr. Rabinowitz co-founded Alexza Pharmaceuticals and served as its vice president for research until 2004, when he joined the faculty of Princeton. There, he has made key scientific contributions to other successful biotechs, including Agios and Kadmon.